scholarly journals Exercise-Induced Changes in Cardiovascular Function after Stroke: A Randomized Controlled Trial

2013 ◽  
Vol 9 (7) ◽  
pp. 883-889 ◽  
Author(s):  
Ada Tang ◽  
Janice J. Eng ◽  
Andrei V. Krassioukov ◽  
Kenneth M. Madden ◽  
Azam Mohammadi ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Cardiovascular Function ◽  
Randomized Controlled ◽  
Exercise Induced ◽  
Induced Changes

scholarly journals Exercise-Induced Changes in Visceral Adipose Tissue Mass Are Regulated by IL-6 Signaling: A Randomized Controlled Trial

2019 ◽  
Vol 29 (4) ◽  
pp. 844-855.e3 ◽  
Author(s):  
Anne-Sophie Wedell-Neergaard ◽  
Louise Lang Lehrskov ◽  
Regitse Højgaard Christensen ◽  
Grit Elster Legaard ◽  
Emma Dorph ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Adipose Tissue ◽  
Visceral Adipose Tissue ◽  
Controlled Trial ◽  
Tissue Mass ◽  
Randomized Controlled ◽  
Adipose Tissue Mass ◽  
Exercise Induced ◽  
Induced Changes ◽  
Visceral Adipose

The Influence of Compression Socks During a Marathon on Exercise-Associated Muscle Damage

2019 ◽  
Vol 28 (7) ◽  
pp. 724-728
Author(s):  
Amanda L. Zaleski ◽  
Linda S. Pescatello ◽  
Kevin D. Ballard ◽  
Gregory A. Panza ◽  
William Adams ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Randomized Controlled Trial ◽  
Muscle Damage ◽  
Controlled Trial ◽  
Blood Samples ◽  
Randomized Controlled ◽  
Direct Measurements ◽  
Exercise Induced ◽  
Objectively Measured ◽  
Induced Changes

Context: Compression socks have become increasingly popular with athletes due to perceived enhancement of exercise performance and recovery. However, research examining the efficacy of compression socks to reduce exercise-associated muscle damage has been equivocal, with few direct measurements of markers of muscle damage. Objective: To examine the influence of compression socks worn during a marathon on creatine kinase (CK) levels. Design: A randomized controlled trial. Setting: 2013 Hartford Marathon, Hartford, CT. Participants: Adults (n = 20) randomized to control (CONTROL; n = 10) or compression sock (SOCK; n = 10) groups. Main Outcome Measures: Blood samples were collected 24 hours before, immediately after, and 24 hours following the marathon for the analysis of CK, a marker of muscle damage. Results: Baseline CK levels did not differ between CONTROL (89.3 [41.2] U/L) and SOCK (100.0 [56.2] U/L) (P = .63). Immediately following the marathon (≤1 h), CK increased 273% from baseline (P < .001 for time), with no difference in exercise-induced changes in CK from baseline between CONTROL (+293.9 [278.2] U/L) and SOCK (+233.1 [225.3] U/L; P = .60 for time × group). The day following the marathon (≤24 h), CK further increased 1094% from baseline (P < .001 for time), with no difference in changes in CK from baseline between CONTROL (+ 1191.9 [1194.8] U/L) and SOCK (+889.1 [760.2] U/L; P = .53 for time × group). These similar trends persisted despite controlling for potential covariates such as age, body mass index, and race finishing time (Ps > .29). Conclusions: Compression socks worn during a marathon do not appear to mitigate objectively measured markers of muscle damage immediately following and 24 hours after a marathon.

scholarly journals The effects of one session of roller massage on recovery from exercise-induced muscle damage: A randomized controlled trial

2020 ◽  
Vol 18 (3) ◽  
pp. 148-154
Author(s):  
Flávia V.A. Medeiros ◽  
Martim Bottaro ◽  
Wagner R. Martins ◽  
Deise L.F. Ribeiro ◽  
Emmanuela B.A. Marinho ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Muscle Damage ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Exercise Induced

scholarly journals Postnatal Enalapril to Improve Cardiovascular Function Following Preterm Preeclampsia (PICk-UP):

Hypertension ◽  
2020 ◽  
Vol 76 (6) ◽  
pp. 1828-1837 ◽  
Author(s):  
Laura Ormesher ◽  
Suzanne Higson ◽  
Matthew Luckie ◽  
Stephen A Roberts ◽  
Heather Glossop ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Global Longitudinal Strain ◽  
Cardiovascular Function ◽  
Left Ventricular ◽  
Targeted Interventions ◽  
Risk Of Death ◽  
Randomized Controlled ◽  
Multicenter Randomized Controlled Trial

Hypertensive disease in pregnancy is associated with future cardiovascular disease and, therefore, provides an opportunity to identify women who could benefit from targeted interventions aimed at reducing cardiovascular morbidity. This study focused on the highest-risk group, women with preterm preeclampsia, who have an 8-fold risk of death from future cardiovascular disease. We performed a single-center feasibility randomized controlled trial of 6 months’ treatment with enalapril to improve postnatal cardiovascular function. Echocardiography and hemodynamic measurements were performed at baseline (<3 days), 6 weeks, and 6 months postdelivery on 60 women. At randomization, 88% of women had diastolic dysfunction, and 68% had concentric remodeling/hypertrophy. No difference was seen in total vascular resistance ( P =0.59) or systolic function (global longitudinal strain: P =0.14) between groups at 6 months. However, women treated with enalapril had echocardiographic measurements consistent with improved diastolic function (E/E′[the ratio of early mitral inflow velocity and early mitral annular diastolic velocity]: P =0.04) and left ventricular remodeling (relative wall thickness: P =0.01; left ventricular mass index: P =0.03) at 6 months, compared with placebo. Urinary enalapril was detectable in 85% and 63% of women in the enalapril arm at 6 weeks and 6 months, respectively. All women responded positively to taking enalapril in the future. Our study confirmed acceptability and feasibility of the study protocol with a recruitment to completion rate of 2.2 women per month. Importantly, postnatal enalapril treatment was associated with improved echocardiographic measurements; these early improvements have the potential to reduce long-term cardiovascular disease risk. A definitive, multicenter randomized controlled trial is now required to confirm these findings. Registration— URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03466333.

scholarly journals FP133Risedronate prevents exercise-induced hypercalcemia; A Randomized Controlled Trial (RCT)

2019 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Masamitsu Senda ◽  
Hamano Takayuki ◽  
Sakaguchi Yusuke ◽  
Yoshitaka Isaka ◽  
Toshiki Moriyama
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Exercise Induced
Sign in / Sign up

Export Citation Format

Share Document